Background and Aims: Lysyl oxidase-like 2 (LOXL2), an amine oxidase, contributes to fibrotic scarring in the tissue by facilitating collagen cross-linking. Recent data demonstrated upregulation of lysyl oxidase and LOXL2 in the fibrotic kidneys after administration of cylosporine A (CsA). Thus, inhibition of LOXL2 may render therapeutic effects against CsA-induced nephropathy by ameliorating tubulointerstitial fibrosis. Method: Low salt fed CD-1 mice were administered olive oil or CsA (15 mg/kg/day, intraperitoneally) for 8 weeks. At 4 weeks, CsA-treated animals were divided into 2 groups respectively and treated with: (1) vehicle, (2) LOXL2 inhibitor (10 mg/kg/day, gavage feeding) for another 4 weeks up to 8 weeks. We explored the reduction of tubulointerstitial fibrosis as well as albuminuria with administration of LOXL2 inhibitor in CsA nephropathy mouse model. Results: CsA administration significantly increased the levels of serum creatinine (9.0 ± 2.0 vs. 25.7 ± 9.2 μmol/L, p=0.038), tubulointerstitial fibrosis (Sirius red, 207.3 ± 49.8 vs. 2082.0 ± 453.2 positive pixels per mm2, p<0.001), F4/80 positive inflammatory cell infiltration in mouse kidney (1.8 ± 0.8 vs. 3.3 ± 2.0 positive cells/field, p<0.001). These changes were associated with upregulated mRNA expression of LOXL2, TGF-β1, and monocyte chemoattractant protein-1 (MCP-1). Administration of LOXL2 inhibitor significantly suppressed the expression of alpha-SMA and collagen 1A, and intrarenal F4/80 positive inflammatory cell infiltrations (19.8 ± 5.5 vs.13.8 ± 1.7 positive cells/field, p=0.029). Moreover, LOXL2 inhibitor effectively reduced albuminuria excretion (44.6 ± 3.3 vs. 27.4 ± 4.3 μg/mg, p=0.007). Conclusion: Our results suggest that LOXL2 inhibitor treatment can attenuate CsA nephropathy progression and LOXL2 inhibitor may be a potential therapeutic target in CsA nephropathy.